Published Medical Literature

Concurrent Leukemia Cutis and Norwegian Scabies: Case Study

Acute Kidney Injury and CLL: Case Study

Can Ibrutinib Enhance CAR T-Cell Production for Patients With CLL?

Selecting Initial Therapy for CLL: Renewed Focus on Minimal Residual Disease

XPO1 Mutation in CLL: Prevalence and Prognostic Value

Patients With CLL in India: Quality-of-Life Analysis

Selecting Among First-Line Therapies in CLL: Does Chemoimmunotherapy Still Play a Role?

Venetoclax Plus Rituximab in Relapsed CLL: Genomic Complexity and Outcomes

Treating Lymphopenia in a Patient With COVID-19 and Treatment-Naive CLL

Ibrutinib Treatment and Response to Fungal Infection in Patients With CLL

Phase II Trial Focuses on Short-Course Fludarabine With Continuous Ibrutinib in CLL

Ibrutinib Interruption in CLL: Pseudo-transformation or True Richter Transformation?

Are Immunoglobulin Alterations Prognostic of Outcomes in CLL?

NOTCH1 Mutation in CLL and Response to Ibrutinib

COVID-19 and CLL: Rare Case of Pseudohypoxemia

Ibrutinib Therapy for CLL: Real-World Outcomes From Denmark

Hematopoietic Cell Transplantation for TP53-Mutant or Deleted CLL: Long-Term Outcomes

How Comorbidities May Affect Response to Idelalisib-Based Therapy in CLL

Fixed-Duration Combination Regimen Under Study in CLL

Swedish Study Centers on Cardiovascular Disease in Patients With CLL

Serious Inpatient Bacterial Infections and Survival in Patients With CLL

Case of Tumor-Lysis Syndrome After Combination CLL Therapy

COVID‐19 and CLL: Case Report of Viral Co-infection With Parainfluenza

Real-World Data From Czech Study Group on CD20 Antibody Plus Chemotherapy for CLL

Can Camptothecin-11 Analog Improve Response to Fludarabine in CLL?

Subcutaneous Versus Intravenous Rituximab in CLL: Canadian Experience

IGHV Mutations and the Relationship Between Translocation and Time to Treatment in CLL

Biomarker May Aid in the Stratification of Prognostic Groups for CLL

Does UGT2B17 Alter Treatment Response in CLL?

Pleural Empyema Caused by Rare Infection in a Patient With CLL

Atypical Case of Chronic Lymphocytic Leukemia Treated With R-CHOP

Novel Prognostic Model May Predict Outcomes in Early-Stage CLL

COVID-19 and CLL: Barcelona Hospital Experience

CAR T-Cell Therapy for CLL: Comparing Doses and Outcomes

Case Reports: Iron Overload Without Blood Transfusion in CLL

Review of Appropriate Therapies for Patients With CLL After Venetoclax Discontinuation

Dosing Schedules May Affect Outcomes With Acalabrutinib in CLL

Long-Term Data Support Ibrutinib Monotherapy in Patients With CLL/SLL

Chemoimmunotherapy vs Chemotherapy in CLL: 5-Year Follow-up of Complement 1 Trial

Do Dose Interruptions Affect Survival in Ibrutinib-Treated Patients With CLL?

Combination Regimens Targeting Multiple Kinases: Fruitful Avenue of CLL Research?

Use of Duvelisib After Ofatumumab in Resistant CLL/SLL

Treatment Potential of CAR-Transduced Natural Killer Cells in CLL

Meta-analysis Supports Maintenance Therapy for Reducing CLL Progression

CLL-Stereotyped Immunoglobulin Gene Rearrangements in Normal B-Cell Subsets

Sequential Combination Therapy for Chronic Lymphocytic Leukemia

Moxetumomab Pasudotox Therapy Under Study in Resistant Hairy Cell Leukemia

Early-Phase Study of Acalabrutinib Plus Obinutuzumab in CLL

Potential Effect of Antigen Drive on T-Cell Repertoire in CLL

Minimal Residual Disease and Chemotherapy-Free Regimens in CLL: Surrogate Prognostic Marker?

CNS Aspergillosis After Ibrutinib Treatment for CLL: A Case Study

Case Study: Multifungal Infection in a Patient Treated With Ibrutinib for CLL

Early Discontinuation of First-Line Ibrutinib in CLL in the Real-World Setting

Response Rates to Venetoclax Plus Ibrutinib in High-Risk CLL

Could a Novel Endogenous Ligand Be a Potential Target for CLL Treatment?

Study Finds MicroRNA Targets p53 Gene in Epstein-Barr Virus–Associated CLL

Combination of Rituximab and High-Dose Methylprednisolone for High-Risk Patients With CLL

Expanding Use of Cyclophosphamide After Transplantation in CLL

Tracking Clonal Evolution in Patients With Stable and Progressive CLL

Exploring the Synergy Between Idelalisib and Bendamustine in Treating CLL

Use of Ibrutinib in CLL: Update 5 Years After Approval

Venetoclax Therapy for Elderly Patients With Resistant CLL

Next-Generation Sequencing and Minimal Residual Disease in Patients With CLL

Five-Year Outcomes With Front-Line Ibrutinib in CLL

CLARITY Trial Update of Ibrutinib Plus Venetoclax in Resistant CLL

Does the Mode of Disease Progression Affect Outcomes in CLL?

Putting Clonal Evolution to Practical Use in Chronic Lymphocytic Leukemia

Survival Outcomes in CLL: Ibrutinib/Rituximab Versus Standard Chemoimmunotherapy

Phase III Trial Shows Venetoclax/Obinutuzumab Active in First-Line Treatment of CLL

Early Results With Cirmtuzumab/Ibrutinib Therapy for CLL

Immunotherapy Under Study in Resistant CLL: ZUMA-8 Trial

Phase II Trial of Acalabrutinib in Ibrutinib-Intolerant Patients With CLL

Gait Speed and Grip Strength: Predictors of Outcome in Hematologic Malignancies?

Newer Treatment Regimen for High-Risk and Older Patients With CLL

Considerations in Selecting Treatment in Resistant CLL

Addition of Ibrutinib to Initial Treatment for Younger Patients With CLL

Long-Term Study Confirms Benefit of Idelalisib in Relapsed CLL

Do Ibrutinib Dose Modifications Affect Long-Term Benefits in CLL?

Natural Killer Cell Function Activated by CD19-Targeted Molecule in CLL

Suboptimal Dosing of Ibrutinib in Patients With CLL

Minimal Residual Disease Status and Long-Term Survival in CLL

Potential of Nitrostyrene Compounds in CLL

Do Risks Outweigh Benefits for Use of Idelalisib Plus Ofatumumab in CLL?